IPST is up +138.43% during Tuesday's regular session, last trading at $17.62 as of 11:07 a.m. ET, versus Monday's close of $7.39. The move follows a roughly -3.4% premarket dip and extends Monday's +235.89% low-float surge, with no conventional same-day press release driving the spike.
Profusa shares are up +233.11% to $15.09 in Tuesday regular trading as of 10:29 a.m. ET, versus Monday's close of $4.53. The move extends premarket and overnight gains after the company's 1-for-4 reverse stock split became effective, reducing shares outstanding from about 2.42 million to roughly 605,726.
WEAV shares climbed +31.83% to $7.29 during regular trading, versus a prior-session close of $5.53. The intraday surge followed Weave's announcement of a definitive agreement to be acquired by Francisco Partners.
AMLX is up +33.08% to $28.52 in regular trading as of 9:40 a.m. ET, versus a $21.43 prior-session close, after surging in Monday after-hours and premarket. Primary catalyst: Amylyx reported positive Phase 3 LUCIDITY topline results for avexitide in post-bariatric hypoglycemia, meeting the primary endpoint with a statistically significant 55% reduction in Level 2/3 hypoglycemic events versus placebo.
KLAR traded at $15.73 in early regular trading, down -19.37% from Monday's $19.51 close; the slide began premarket after Q2 results. Q2 beat estimates—revenue rose +27% to $1.04B and adjusted EPS of +$0.01 exceeded a -$0.05 loss consensus—but guidance drove the selloff.
Fabrinet (FN) is trading down -14.28% at $513.11 during the regular session, versus Monday's close of $598.58. The move follows fiscal Q4 results released after Monday's close; shares fell ~7% after-hours and extended losses in premarket trading.
Selected price target: $43, matching the highest published Wall Street analyst target for CNK in recent months. Current position: Cinemark shares recently traded near $37.50, just below the 52-week high of $38.98, leaving roughly 15% upside to the $43 target.
NIQ Global Intelligence shares rose 56.8% in the 30-day period ended August 17, 2026, climbing from $11.00 to $17.25. The move accelerated sharply after second-quarter 2026 results, when adjusted EPS of $0.27 beat a consensus estimate near $0.20.
BETA shares advanced about 44% over the last 30 days, from a $17.76 close on July 17, 2026, to $25.60 on Aug. 17, 2026. Over the trailing quarter, the stock has climbed roughly 66% from a $15.41 close on May 15, 2026.
Ondas Inc. ( ONDS ) closed near $9.00 in mid-August 2026, so a move to the $20 stock price target would require roughly 120% upside. The strongest bull case rests on record second-quarter 2026 revenue, raised full-year guidance, a growing order backlog, and U.S. policy tailwinds for domestic drone and defense technology.
Oil and natural gas price fluctuations remain the primary macroeconomic sensitivity, directly influencing exploration and production (E&P) capital expenditure budgets and rig demand. Helmerich & Payne’s FlexRig technology and efficiency-focused fleet position the company to benefit from industry shifts toward higher-specification, lower-emission drilling solutions.
Paymentus Holdings shares rose about 36.5% over the 30 days through the August 17, 2026 close, climbing from $29.78 to $40.66. The primary catalyst was second-quarter 2026 results reported August 3, 2026: record revenue of $360.7 million, up 28.8% year over year, with adjusted EBITDA up 54%.
MMED shares climbed roughly 15.4% over the last 30 days, from a closing price of $16.93 on July 17, 2026, to $19.53 at the latest available close. The advance was supported by expanded U.S. Medicare access to the MiniMed Flex system, the start of commercial U.S. shipments with Abbott's Instinct sensor, and favorable analyst actions.
Upcoming data presentations in the second half of 2026 and a planned Phase 3 registrational trial for the lead candidate zolucatetide in desmoid tumors during the first half of 2027 represent major clinical catalysts. The company’s Helicon discovery platform targets historically undruggable intracellular proteins, positioning it competitively in oncology and rare disease segments with potential for expanded pipeline applications.
Selected price target: $40 per share, roughly 38% above the most recent close near $29. Strongest bullish factors: accelerating security and compute revenue, AI-driven traffic growth, expanding gross margins, and improving free cash flow.
Selected price target: $10, roughly 56% above the latest close of $6.39 for Archer Aviation Inc. (NYSE: ACHR) . Strongest bullish factors: a Wall Street consensus Buy rating with average analyst price targets clustered near $10.60–$11.80, the planned acquisition of three Boeing-owned aerospace businesses, and progress toward FAA certification and early commercial operations.
ExlService Holdings continues to emphasize artificial intelligence (AI) integration across its data analytics and operations management services, positioning the company for potential expansion in banking, insurance, and healthcare verticals. Upcoming quarterly earnings releases, including the expected Q3 2026 report, and ongoing integration of strategic acquisitions represent key near-term catalysts that could shape investor sentiment.
Caris Life Sciences continues to advance its AI-driven molecular profiling platforms, with upcoming launches such as Caris Detect positioned to expand its addressable market in multi-cancer early detection. Company guidance points to 2026 revenue in the $1.03 billion to $1.04 billion range, supported by projected 20% growth in clinical therapy selection volumes.
The central price objective is $15 , roughly 22% above the latest close near $12.31. Stronger steel pricing, automotive contract momentum, and a return to positive free cash flow are the main bullish factors.
ZETA shares rose approximately 33% in the last 30 days, from a closing price of $21.68 on July 17, 2026, to $28.83 on August 17, 2026. The move accelerated after Zeta Global reported second-quarter 2026 results on August 4, delivering its 20th consecutive beat-and-raise quarter.